CODX
Co-Diagnostics, Inc.·Healthcare
1.37
4.861%(−0.07)
Market ClosedLast Updated: — ET
52W L: $1.3552W H: $46.50
CODX NEWS
prnewswire.com
2d ago
Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah
Trade mission itinerary of business, government, and industry briefings across Switzerland and Germany to include site visits to Roche Diagnostics, UBS, Zurich Innovation Park and more SALT LAKE CITY, April 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced Company executives will be participating in the latest World Trade Center (WTC) Utah trade mission with Utah Governor Cox and the Governor's Office of Economic Opportunity, taking place April 13-22 in locations across Switzerland and Germany. "Switzerland and Germany are home to many of the world's leading technology, diagnostics, financial and R&D environments," said Dwight Egan, Chief Executive Officer, Co-Diagnostics, Inc. "We are pleased to be part of this prestigious trade mission and to help further the goals of our community, while strengthening our own international network of strategic partners and advancing important Co-Dx initiatives.
seekingalpha.com
Apr 1
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
prnewswire.com
Mar 31
Co-Diagnostics Reports Full Year 2025 Financial Results
Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform Strengthening Technology Leadership with AI Integration and Expanding IP Portfolio SALT LAKE CITY, March 31, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results: Revenue of $0.6 million, compared to $3.9 million in 2024, primarily due to lower grant revenue Operating expenses of $50.6 million, compared to $43.0 million in 2024, driven by a non-cash impairment charge of $18.9 million from revaluation of intangible assets Operating loss of $50.2 million, compared to $40.1 million in 2024 Net loss of $46.9 million, or $35.25 per share, compared to net loss of $37.6 million, or $37.22 per share in 2024, primarily due to intangible asset impairment charges and lower grant revenue, partially offset by decreases in operating expenses and a benefit from income taxes Adjusted EBITDA loss of $28.0 million, compared to a loss of $33.5 million in 2024 Cash, cash equivalents, and marketable investment securities totaled $11.9 million as of December 31, 2025, compared to $29.7 million as of December 31, 2024 Full Year 2025 Business Highlights: Closed $3.8 million offering of 9.62 million shares of common stock at an offering price of $0.40 per share on a pre-reverse split basis Closed $7.0 million offering of 12.7 million shares of common stock at an offering price of $0.55 per share on a pre-reverse split basis Continued advancement of CoSara Diagnostics joint venture in India, including regulatory progress and manufacturing readiness for PCR Pro® instrument* Signed definitive agreement with Arabian Eagle to establish CoMira Diagnostics joint venture in Saudi Arabia; currently progressing on execution and finalizing lease for manufacturing facility Initiated and advanced clinical evaluations of upper respiratory multiplex test Further progressed development across pipeline programs, including tuberculosis (TB) and HPV tests Expanded the AI business unit, integrating machine learning capabilities into the Co-Dx™ Primer Ai™ platform Strengthened the intellectual property portfolio with a new international patent granted in Australia Engaged Maxim Group to pursue SPAC transaction for CoSara Diagnostics Received recognition from Utah Governor's Office and BioUtah for the formation of CoMira Diagnostics Recent Developments: Received CDSCO license to manufacture and sell the CoSara PCR Pro® instrument in India, representing a key regulatory milestone and enabling commercialization readiness Signed an agreement to expand CoSara Diagnostics' commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal, and Sri Lanka, increasing the regional addressable market to approximately $13 billion Initiated shipments of PCR Pro® instruments and tuberculosis (TB) test* materials to India to support upcoming clinical performance studies, with the instrument and test kits being aligned with new WHO guidance on TB testing Strengthened the intellectual property portfolio with a new international patent granted in Japan "Over the past year, we made meaningful progress across multiple initiatives that have positioned the Company for its next phase of growth, including advancing our clinical pipeline, expanding our global footprint, and preparing for commercialization of the platform in 2026," said Dwight Egan, Chief Executive Officer of Co-Diagnostics.
prnewswire.com
Mar 25
Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization
The near-term commencement of clinical studies is expected to align with recent WHO tuberculosis recommendations for near-point-of-care molecular testing and utilizing tongue swab samples New recommendations are aligned with the design of Co-Dx's proprietary test, platform, and mission SALT LAKE CITY, March 25, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has commenced shipments of PCR Pro ® instruments*, Co-Dx™ PCR MTB test kits* for tuberculosis ("TB"), and proprietary sample preparation instruments to its joint venture CoSara Diagnostics Pvt. Ltd. ("CoSara") in India.
benzinga.com
Mar 25
EXCLUSIVE: Co-Diagnostics Ships Diagnostic Tests To India Ahead Of TB Study Launch
These materials are necessary to begin clinical performance studies of the TB test on the PCR platform, as the company completes final steps toward initiating those studies in the near term.
prnewswire.com
Mar 20
Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
Expansion into Bangladesh, Pakistan, Nepal, and Sri Lanka increases TAM in region to $13 billion and supports commercialization strategy for the PCR Pro ® and SARAGENE ® product line SALT LAKE CITY, March 20, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company has signed an agreement for CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited ("ASE Group"), to significantly expand its commercial and distribution territory across South Asia to now include Bangladesh, Pakistan, Nepal, and Sri Lanka.
